GREY:ICOTF - Post by User
Comment by
allain250on Jun 23, 2018 7:16pm
84 Views
Post# 28219251
RE:RE:Smoke On The Water
RE:RE:Smoke On The WaterNovember 22, 2017, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: ICO) (OTCQB: ICOTF and its recently formed subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has been granted ethics approval in Australia to conduct its proposed Phase 1 clinical study for Oral Amphotericin B. Amphotericin B is a well-known approved drug for the treatment of fungal and parasitic infections but the therapy is currently limited by intravenous infusion. iCo Therapeutics is developing a proprietary oral reformulation of Amphotericin B. “Entry into the first clinical trial for the Company’s Oral Amphotericin B candidate is a major corporate milestone for iCo Therapeutics” stated Andrew Rae, President and CEO of iCo Therapeutics Inc. “We currently look forward to study results from this Phase 1 trial in the first half of 2018.” Stated Dr. Kishor Wasan, Professor and Dean, College of Pharmacy and Nutrition, University of Saskatchewan, Adjunct Professor Faculty of Pharmaceutical Sciences, University of British Columbia and co-inventor, "this a major milestone for the Oral Amphotericin B technology and our research team. We are grateful to iCo Therapeutics for their support throughout multiple years of pre-clinical development and driving this technology to the clinic."